{"id":6450,"date":"2018-01-01T14:28:34","date_gmt":"2018-01-01T14:28:34","guid":{"rendered":"https:\/\/www.olartemoure.com\/web\/?p=6450\/"},"modified":"2018-01-24T16:11:00","modified_gmt":"2018-01-24T16:11:00","slug":"om-weekly-digest-05-01-2018","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/","title":{"rendered":"OM Weekly Digest (05-01-2018)"},"content":{"rendered":"

<\/a><\/p>\n

..<\/span><\/p>\n

\n

COLOMBIA |\u00a0Patents, Regulatory | Colombia\u00a0starts a\u00a0Declaration of Public Interest Procedure (seeking a Compulsory License) for Hepatitis C antivirals<\/u><\/strong><\/h3>\n

\"\"<\/a><\/p>\n

By means of\u00a0Resolution 5146\/2017<\/a><\/span>, the Colombian Ministry of Health (MoH) announced that it will evaluate if there are reasons for\u00a0a Declaration of Public Interest -DIP- seeking a Compulsory License -CL-) regarding direct-acting antivirals for the treatment of hepatitis C.<\/p>\n

The decision was adopted, since a NGO asked the MoH\u00a0to declare the public interest of\u00a0patents covering medicines\u00a0against Hepatitis C\u00a0which are based in\u00a0the following active principles (but not limited to):<\/p>\n

– Boceprevir; Daclatasvir; Dasavubir; Elbasvir; Faldaprevir; Gazoprevir; Ledispasvir; Ombitasvir; Paritaprevir; Simeprevir; Sofosbuvir;\u00a0and Telaprevir.<\/p>\n

For now\u00a0is unknown which patents would be\u00a0subject of this\u00a0DIP Procedure, because the Colombian Patent Office (SIC in Spanish) and the Regulatory Authority (INVIMA in Spanish) have not yet established the relationship between those\u00a0and medicines (Marketing Approvals) covered.<\/p>\n

Accordingly,\u00a0the start date of the\u00a0DIP Procedure would be made known to patent holders only until the SIC and INVIMA (in an internal procedure) inform\u00a0MoH about the patent-medicine relationship.<\/p>\n

There will be a period of 15 working days (counted from the\u00a0notification date) for patents titleholders to\u00a0intervene\u00a0in the DIP Procedure.\u00a0 Within that same term any third party may intervene.<\/p>\n

Documentation related to the DIP process for LO purposes is available in the following links (one<\/a><\/span>\u00a0and\u00a0two<\/a><\/span>).<\/p>\n

.<\/span><\/p>\n<\/div>\n

\n
\n
\n
\n
\n

COLOMBIA\u00a0|\u00a0Regulatory | Colombia will establish criteria for centralized purchase and supply of medicines<\/u><\/strong><\/h3>\n<\/div>\n

\"\"<\/a><\/p>\n

The Colombian Ministry of Health released a Draft Resolution<\/a><\/span>, through which it will establish criteria for the centralized purchase, distribution and supply of medicines.<\/p>\n

Specifically, it will establish the mechanism to carry out the centralized purchase and distribution of medicines for the treatment of prioritized diseases.<\/p>\n

The draft Resolution can be viewed in\u00a0the following link.<\/p>\n<\/div>\n

\n

.<\/span><\/h3>\n
\n
\n
\n

COLOMBIA\u00a0|\u00a0Regulatory |\u00a0Requirements for the manufacture and commercialization of alcoholic beverages in Colombia will be updated<\/strong><\/span><\/h3>\n

\"\"<\/a><\/p>\n

On 29 December 2017, the Ministry of Health of Colombia\u00a0announced a Draft Decree through which would partially amend Decree 1686\/2012<\/a><\/span>, which establishes the requirements for the manufacture, marketing, export and import of alcoholic beverages for human consumption.<\/p>\n

Specifically,\u00a0the Draft Decree proposes that alcoholic beverages manufactured and marketed in\u00a0Colombia must\u00a0comply with Good Manufacturing Practices (GMP) requirements.<\/p>\n

Comments may be submitted\u00a0until 26 January 201<\/span>8<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

.<\/span><\/p>\n<\/div>\n

\n
\n

COLOMBIA\u00a0| Patents, Trademarks| Colombian\u00a0Patent and Trademark Office made effective Fees Increase<\/strong><\/span><\/h3>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n

\"\"<\/a><\/p>\n

Starting\u00a01 January 2018, the increases made by the Colombian Patent and Trademark Office (SIC in Spanish) became effective.<\/p>\n

As we\u00a0announced in a previous OM Weekly Digest edition<\/a><\/span>, the fee updates meant an average 6% increase in all filing and prosecution\u00a0fees of patents, trademarks and others distinctive signs and new creations.<\/p>\n

As a novelty, the Resolution expressly stated that there will be no refund of fees paid for any reason.<\/p>\n

\n

.<\/span><\/p>\n<\/div>\n

\n
\n

COLOMBIA\u00a0| Consumer Law\u00a0| New Regime of Protection for Colombian Telecommunications Users entered into force<\/strong><\/span><\/h3>\n<\/div>\n

\"\"<\/a><\/p>\n

Starting 1 January 2018, Colombia has a New Regime for the Right Protection of the Communications Services Users, issued by the Communications Regulation Commission (CRC).<\/p>\n

Although the New Regime was released on 24 February 2017 (through\u00a0CRC Resolution 5111\/2017<\/a><\/span>), it has been updated on different occasions during 2017.<\/p>\n

The New Regime is applicable to telephony, internet and television services, and its socialization will be carried out\u00a0with the help of\u00a0the Superintendence of Industry and Commerce.<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

.. COLOMBIA |\u00a0Patents, Regulatory | Colombia\u00a0starts a\u00a0Declaration of Public Interest Procedure (seeking a Compulsory License) for Hepatitis C antivirals By means of\u00a0Resolution 5146\/2017, the Colombian Ministry of Health (MoH) announced that it will evaluate if there are reasons for\u00a0a Declaration of Public Interest -DIP- seeking a Compulsory License -CL-) regarding direct-acting antivirals for the treatment […]<\/p>\n","protected":false},"author":1,"featured_media":6709,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-6450","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsletter-en"],"yoast_head":"\nOM Weekly Digest (05-01-2018) - OlarteMoure | Intellectual Property<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OM Weekly Digest (05-01-2018)\" \/>\n<meta property=\"og:description\" content=\".. COLOMBIA |\u00a0Patents, Regulatory | Colombia\u00a0starts a\u00a0Declaration of Public Interest Procedure (seeking a Compulsory License) for Hepatitis C antivirals By means of\u00a0Resolution 5146\/2017, the Colombian Ministry of Health (MoH) announced that it will evaluate if there are reasons for\u00a0a Declaration of Public Interest -DIP- seeking a Compulsory License -CL-) regarding direct-acting antivirals for the treatment […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-01T14:28:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-01-24T16:11:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/01\/Antiviral.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"849\" \/>\n\t<meta property=\"og:image:height\" content=\"565\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"headline\":\"OM Weekly Digest (05-01-2018)\",\"datePublished\":\"2018-01-01T14:28:34+00:00\",\"dateModified\":\"2018-01-24T16:11:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/\"},\"wordCount\":545,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/Antiviral.jpg\",\"articleSection\":[\"Newsletter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/\",\"name\":\"OM Weekly Digest (05-01-2018) - OlarteMoure | Intellectual Property\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/Antiviral.jpg\",\"datePublished\":\"2018-01-01T14:28:34+00:00\",\"dateModified\":\"2018-01-24T16:11:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/Antiviral.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/Antiviral.jpg\",\"width\":849,\"height\":565,\"caption\":\"virus on a blue background\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-05-01-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OM Weekly Digest (05-01-2018)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OM Weekly Digest (05-01-2018) - OlarteMoure | Intellectual Property","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/","og_locale":"en_US","og_type":"article","og_title":"OM Weekly Digest (05-01-2018)","og_description":".. COLOMBIA |\u00a0Patents, Regulatory | Colombia\u00a0starts a\u00a0Declaration of Public Interest Procedure (seeking a Compulsory License) for Hepatitis C antivirals By means of\u00a0Resolution 5146\/2017, the Colombian Ministry of Health (MoH) announced that it will evaluate if there are reasons for\u00a0a Declaration of Public Interest -DIP- seeking a Compulsory License -CL-) regarding direct-acting antivirals for the treatment […]","og_url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2018-01-01T14:28:34+00:00","article_modified_time":"2018-01-24T16:11:00+00:00","og_image":[{"width":849,"height":565,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/01\/Antiviral.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/"},"author":{"name":"admin","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"headline":"OM Weekly Digest (05-01-2018)","datePublished":"2018-01-01T14:28:34+00:00","dateModified":"2018-01-24T16:11:00+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/"},"wordCount":545,"commentCount":0,"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/01\/Antiviral.jpg","articleSection":["Newsletter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/","url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/","name":"OM Weekly Digest (05-01-2018) - OlarteMoure | Intellectual Property","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/01\/Antiviral.jpg","datePublished":"2018-01-01T14:28:34+00:00","dateModified":"2018-01-24T16:11:00+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"breadcrumb":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/01\/Antiviral.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/01\/Antiviral.jpg","width":849,"height":565,"caption":"virus on a blue background"},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-05-01-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"OM Weekly Digest (05-01-2018)"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/olartemoure.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/6450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=6450"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/6450\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/6709"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=6450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=6450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=6450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}